

# In-Silico Anti-Diarrhoeal Evaluation of Lagu Gangathara Chooranam

## Research Article

Anandhalakshmi D<sup>1\*</sup>, Pavithra A<sup>1</sup>, Surya A<sup>1</sup>, Nalini Sofia H<sup>2</sup>,  
Vetha Merlin Kumari H<sup>2</sup>, Lakshmikantham T<sup>2</sup>, Meenakumari R<sup>3</sup>

1. PG scholar, 2. Associate Professor, 3. Director,  
Department of Maruthuvam, National Institute of Siddha, Chennai. Tamil Nadu. India.

### Abstract

**Background:** In siddha system of medicine diarrhoea can be compared with *kazhichal*. Diarrhoea results from several factors like intestinal hyper-motility, malabsorption of water, inflammation of GIT or use of laxatives. In siddha literature, the preparation named *lagu gangathara chooranam* is indicated for *kazhichal*. **Aim:** The study aims to perform the in-silico computational studies of phytoconstituents of the siddha formulation *lagu gangathara chooranam* targeted against m3 muscarinic acetyl choline receptor for anti-diarrhoeal activity. **Methods:** The retrieved phytoconstituents were subjected for docking calculations against target enzyme m3 muscarinic acetylcholine receptor. **Results:** The computational analysis retrieved 11 bio-active compounds from herbal formulation. It includes limonene,  $\alpha$ -humulene, cyperolone, lupeol, beta amyrin, betulinic acid, mangiferin, quercetin, caryophyllene and luteolin. These compounds significantly bind against the target m3 muscarinic acetylcholine receptor. Hence these phytoconstituents may produce significant anti-diarrheal activity by hindering the activity of m3 muscarinic acetylcholine receptor in the intestinal region which mediates the diarrhoea. **Conclusion:** Further clinical trials or experimental studies could be conducted to confirm the effectiveness of this siddha formulation *lagu gangathara chooranam* against diarrhoea.

**Keywords:** Molecular docking, *Lagu Gangathara Chooranam*, Antidiarrhoeal activity, M3 muscarinic Acetylcholine receptor, Siddha.

### Introduction

Diarrhea is defined as the passage of stools of fluid consistency more frequently than in usual [usually more than 3 times per day]. The wet weight of the stool is increased (1). The approximate volume of water in stools is 200g/day in teenagers and adults whereas in children/infants it is 10 mL/Kg/day. Diarrhea is caused by the imbalance in the absorption of ions, other substrates and water by the small and large intestine (2). Based on the duration, diarrhea can be classified as acute and chronic diarrhea (3). Infections or irritants cause acute diarrhea whereas chronic diarrhea results from many causes (1). Chronic diarrhea tends to be non-infectious due to malabsorption, inflammatory bowel disease and side effects of medications. (3). In young children Rota virus causes severe diarrhea globally. One fifth of the infectious diarrhea is caused by Norovirus in both children and adults. Noro virus is about to cause death in 200000 deaths in developing country annually (4). In India, the prevalence of diarrhea in 2007-2008 was estimated as 0.1-33.8% and in

2015-2018 it was 0.6-29.1% (5,6). As per WHO and UNICEF, every year 2.5 billion diarrheal cases and 1.9 million children below the age of 5 years die globally (7). Anti-diarrheal drugs stop diarrhea by decreasing the propulsive movement of GI smooth muscles or by reducing the secretions of the intestine (8). Due to contraindications, drug resistance and adverse effects of the currently available drugs there is a need for alternative medicines to treat diarrhea (9,10). Siddha system is one of the unique traditional system of medicine with vast literatures. *Lagu Gangathara Chooranam* is one of the Siddha herbal formulations indicated for Kazhichal (11). Kazhichal can be compared with diarrhoea in Siddha. Molecular docking can be defined as how the drug and enzyme or protein fit together. The phytoconstituents bind with target's core amino acids [Ser151, Tyr529, Tyr506, and Trp503] using hydrogen bond to hinder the function of the M3 muscarinic acetylcholine receptor [PDB – 4U14]. This receptor is responsible for motility and peristalsis which mediates the diarrheal activity. Among the mAChR group, M3 subtype play many significant physiological functions such as glandular secretion and smooth muscle contraction (12-17). Thereby phytoconstituents which inhibit the target muscarinic acetylcholine receptor by occupying the residual active amino acids could preferably block the intestinal motility and thereby establish the anti-diarrhoeal activity. The aim of this study is to analyse the Anti-diarrheal activity of *Lagu Gangathara Chooranam* which is a siddha herbal

#### \* Corresponding Author:

**Anandhalakshmi**

PG Scholar,

Department of Maruthuvam,

National Institute of Siddha.

Chennai. Tamil Nadu. India.


Email Id: [anandhalakshmid@gmail.com](mailto:anandhalakshmid@gmail.com)

formulation containing *Aegle marmelos L.*, *Cyperus rotundus L.*, *Wrightia tinctoria R.Br.*, *Symplocos racemose Roxb.*, *Bombax ceiba L.*, *Saccharum officinarum L.*

### Methodology

Based on the literature review, the phytochemicals from the medicinal plants possessing were retrieved (18-24). The retrieved phytocomponents were subjected for docking calculations against target enzyme M3 muscarinic acetylcholine receptor. Essential hydrogen atoms, Kollman united atom type charges, and solvation parameters were added with the aid of AutoDock tools [Affinity [grid] maps of  $\times\times$  Å grid points and 0.375 Å spacing were generated using the Autogrid program (25). AutoDock parameter set- and distance-dependent dielectric functions were used in the calculation of the van der Waals and the electrostatic terms, respectively. Docking simulations were performed using the Lamarckian genetic algorithm [LGA] and the Solis & Wets local search method (26). Initial position, orientation, and torsions of the ligand molecules were set randomly. All rotatable torsions were released during docking. Each docking experiment was derived from 2 different runs that were set to terminate after a maximum of 250000 energy evaluations. The population size was set to 150. During the search, a translational step of 0.2 Å, and quaternion and torsion steps of 5 were applied.

**Table 1: Details of Target**


PDB	Name of the Target	Figure 1: M3 muscarinic acetylcholine receptor -PDB- 4U14
4U14	M3 muscarinic acetylcholine receptor	

**Table 2: List of Phytocomponents selected for docking**


Herbs	Phytochemicals
<i>Aegle marmelos L.</i>	<ul style="list-style-type: none"> <li>• Limonene</li> <li>• <math>\alpha</math>-Humulene</li> </ul>
<i>Cyperus rotundus L.</i>	<ul style="list-style-type: none"> <li>• Cyperolone</li> </ul>
<i>Wrightia tinctoria R.Br</i>	<ul style="list-style-type: none"> <li>• Lupeol</li> <li>• Beta Amyrin</li> </ul>
<i>Symplocos racemosa Roxb.</i>	<ul style="list-style-type: none"> <li>• Betulinic acid</li> <li>• Oleanolic acid</li> </ul>
<i>Bombax ceiba Linn</i>	<ul style="list-style-type: none"> <li>• Mangiferin</li> <li>• Quercetin</li> </ul>
<i>Woodfordia fruticosa Kurz</i>	<ul style="list-style-type: none"> <li>• Caryophyllene</li> </ul>
<i>Saccharum officinarum Linn</i>	<ul style="list-style-type: none"> <li>• Luteoline</li> </ul>

**Figure 2: 2D and 3D Structure of Selected Ligands**


**Figure 2.1: Limonene**




**Figure 2.2:  $\alpha$ -Humulene**




**Figure 2.3: Cyperolone**



**Figure 2.4: Lupeol**




**Figure 2.5: Beta Amyrin**




**Figure 2.6: Betulinic acid**

Ligand in 2D




Ligand in 3D




**Figure 2.7: Oleanolic acid**

Ligand in 2D




Ligand in 3D




**Figure 2.8: Mangiferin**

Ligand in 2D




Ligand in 3D




**Figure 2.9: Quercetin**

Ligand in 2D




Ligand in 3D




**Figure 2.10: Caryophyllene**

Ligand in 2D




Ligand in 3D




**Figure 2.11: Luteolin**

Ligand in 2D




Ligand in 3D




**Figure 2.12: Loperamide**

Ligand in 2D



Ligand in 3D



## Results and Discussion

*Lagu Gangathara Chooranam* is a polyherbal formulation containing 6 raw drugs. Among those, *Aegle marmelos L* possesses Anti-inflammatory, Antibacterial and Anti-diarrhoeal activity (29). *Cyperus rotundus L.* have Antidiarrhoeal and Anti-emetic activity (30). *Symplocos racemose Roxb* possess antimicrobial, Analgesic, anti-inflammatory and anti-diarrheal activity (31,32). *Wrightia tinctoria R.Br* possess antibacterial activity (33). *Woodfordia fruticosa [L] Kurz* possess anti-inflammatory, antibacterial, anti-ulcer and antimicrobial activity(34). *Bombax ceiba L* have antimicrobial and anti-inflammatory activity (35). From data of the herb, 11 lead compounds such as Limonene,  $\alpha$ -Humulene, Cyperolone, Lupeol, Beta Amyrin, Betulinic acid, Mangiferin, Quercetin, Caryophyllene and Luteolin possess significant binding efficacy by interacting with the core target amino acids.

Loperamide exhibits significant antidiarrheal activity by reducing the gut motility. Loperamide acts via the peripheral opioid receptors with limited access to CNS(36). Loperamide is considered as a standard drug to compare the efficacy of the test drug *Lagu Gangathara Chooranam*. Cyperolone has highest binding affinity of -7.63 kcal/mol Caryophyllene has binding affinity of -7.57 kcal/mol, followed by  $\alpha$ -Humulene with -7.48 kcal/mol, Quercetin with -7.26 kcal/mol, Luteolin - 7.24kcal/mol, betulinic acid with -6.86 kcal/mol, beta amyrin with -6.31 kcal/mol, Limenone with -5.50 kcal/mol, Mangiferin with -5.45 kcal/mol, Lupeol with -3.12 kcal/mol and Oleanolic acid with -2.53 kcal/mol with the core aminoacids Ser151, Tyr529, Tyr506, and Trp503 of the M3 muscarinic acetylcholine receptor. Loperamide has the binding affinity of about -7.57 kcal/mol. But the cyperolone possess higher binding energy of about

-7.63 kcal/mol than loperamide [-7.57 kcal/mol]. But the other drugs possess anti-microbial, antibacterial and anti-diarrhoeal activity that makes the drug more effective in treating diarrhea. Among the 11 compounds, Limonene, Cyperolone, Betulinic acid, Mangiferin, Quercetin, Caryophyllene showed 4 interactions with amino acid residue [Ser151, Tyr529, Tyr506, and Trp503].  $\alpha$ -Humulene and Beta Amyrin showed 3 interactions with the core amino acid residue Ser151, Tyr506, and Trp503. Lupeol and luteolin showed 3 interactions with the core amino acid residue Tyr529, Tyr506, and Trp503. Oleonic acid showed 3 interactions with the core amino acid residue Ser151, Tyr506. Loperamide possess 4 interactions with the core amino acid residue Ser151, Tyr506, Trp503 and TYR529. In this drug, Cyperolone possess 4 interactions as same as loperamide. Quercetin was reported to have protection and benefits against chronic inflammation of the intestine (37). Added quercetin affects the progression of the diseases such as IBD and colitis (38). Luteolin possess strong anti-inflammatory activity and have therapeutic efficacy against IBD (39,40,41). Betulinic acid and oleanolic acid have gastroprotective and anti-ulcer activity (42). A study reported that both betulinic acid and oleanolic acid have the ability to suppress the diarrhea induced by Lt[Heat labile enterotoxin] at 4mM, which is less than LD50 in mice (43). Oleanolic acid and betulinic acid binds with heat labile enterotoxin [LT] with the binding energy -11.76 kcal/mol and -10.99 kcal/mol respectively. Oleonic acid formed hydrophobic bonds with Gly33,

Trp88, Lys 91 and Lys34 whereas betulinic acid binds with Gly33, Trp88, Lys 91 and Gln56 residues of LTB (44). In a study done in Male Swiss albino rats, diarrhoea was induced using castor oil. Administration of minimal doses of limonene reduced the intestinal content volume by 28.52% (45). Electrolyte balance in the intestine cells is essential for gut health in animals. In animals, ricinolic acid increases the permeability of electrolytes by inhibiting  $\text{Na}^+/\text{K}^+$  ATPase thereby increases the severity of diarrhea. Luteolin was found to be effective in increasing the activity of  $\text{Na}^+/\text{K}^+$  ATPase and increases the concentration of  $\text{Na}^+$  and  $\text{K}^+$  in the small intestine. In molecular docking study, luteolin binds with the amino acids TYR-443, TYR-32 of  $\text{Na}^+/\text{K}^+$  ATPase. This indicates that luteolin possess potent antidiarrheal activity (46). In a docking study for antidiarrhoeal activity, Loperamide binds with kappa and delta opioid receptor with the binding energy of about -6.6 and -10.1 kcal/mol. While, beta amyrin had binding energy of about -4.3 to -7.9 kcal/mol with human-kappa opioid receptor (47). But in this study beta amyrin binds with M3 muscarinic acetylcholine receptor with the binding energy of about -6.31 kcal/mol. Finally, this study states that 11 lead components bind with core amino acids [Ser151, Tyr529, Tyr506, and Trp503] on the target with 75-100% binding efficacy with the target receptor M3 muscarinic acetylcholine receptor -PDB- 4U14. This shows that the siddha preparation *Lagu Gangathara Chooranam* possess promising antidiarrhoeal activity.

**Table 3: Ligand Properties of the Compounds Selected for Docking Analysis**

Compound	Molar weight g/mol	Molecular Formula	H Bond Donor	H Bond Acceptor	Rotatable bonds
Limonene	136.23 g/mol	C10H16	0	0	1
$\alpha$ -Humulene	204.35 g/mol	C15H24	0	0	0
Cyperolone	236.35 g/mol	C15H24O2	1	2	2
Lupeol	426.729 g/mol	C30H50O	1	1	1
Beta Amyrin	426.7 g/mol	C30H50O	1	1	0
Betulinic acid	456.7 g/mol	C30H48O3	2	3	2
Oleanolic acid	456.711 g/mol	C30H48O3	2	3	1
Mangiferin	422.342 g/mol	C19H18O11	8	11	2
Quercetin	302.23 g/mol	C15H10O7	5	7	1
Caryophyllene	204.35 g/mol	C15H24	0	0	0
Luteolin	286.24g/mol	C15H10O6	4	6	1
Loperamide	477 g/mol	C29H33CIN2O2	1	3	7

**Table 4: Summary of the molecular docking studies of compounds against M3 muscarinic acetylcholine receptor -PDB- 4U14**

Compounds	Est. Free Energy of Binding	Est. Inhibition Constant, Ki	Electrostatic Energy	Total Intermolec. Energy	Interact. Surface
Limonene	-5.50 kcal/mol	93.68 Um	-0.01 kcal/mol	-5.79 kcal/mol	434.098
$\alpha$ -Humulene	-7.48 kcal/mol	3.27 Um	-0.22 kcal/mol	-7.48 kcal/mol	635.225
Cyperolone	-7.63 kcal/mol	2.56 uM	-0.12 kcal/mol	-7.79 kcal/mol	612.282
Lupeol	-3.12 kcal/mol	5.20 Mm	-0.08 kcal/mol	-3.71 kcal/mol	974.617


Beta Amyrin	-6.31 kcal/mol	23.87 Um	-0.21 kcal/mol	-5.46 kcal/mol	738.836
Betulinic acid	-6.86 kcal/mol	9.40 Um	-0.18 kcal/mol	-6.40 kcal/mol	719.055
Oleanolic acid	-2.53 kcal/mol	13.91 mM	-0.03 kcal/mol	-3.17 kcal/mol	958.768
Mangiferin	-5.45 kcal/mol	100.95 uM	-0.16 kcal/mol	-4.32 kcal/mol	815.729
Quercetin	-7.26 kcal/mol	4.74 uM	-0.13 kcal/mol	-6.45 kcal/mol	707.124
Caryophyllene	-7.57 kcal/mol	2.84 uM	-0.09 kcal/mol	-7.57 kcal/mol	584.688
Luteolin	-7.24 kcal/mol	4.94 uM	-0.14 kcal/mol	-7.33 kcal/mol	698.265
Loperamide	-7.57 kcal/mol	2.84 uM	-0.15 kcal/mol	-7.57 kcal/mol	585.278

**Table 5: Amino acid Residue Interaction of Lead and Standard against M3 muscarinic acetylcholine receptor -PDB- 4U14**

Compounds	Interactions	Amino acid Residues															
		116	147	148	151	503	506	529	532	533							
Limonene	4	ILE	ASP	TYR	SER	TRP	TYR	TYR	CYS	TYR							
α-Humulene	3	TYR	SER	ASN	TRP	ALA	ALA	PHE	TRP	TYR	ASN	CYS					
Cyperolone	4	ASP	TYR	SER	TRP	TYR	TYR	CYS	TYR								
Lupeol	3	TYR	ILE	LEU	THR	ALA	ALA	PHE	TRP	TYR	ASN	VAL	TRP	TYR			
Beta Amyrin	3	TYR	SER	ASN	TRP	ILE	ILE	THR	THR	ALA	ALA	TRP	TYR	ASN	VAL	TRP	
Betulinic acid	4	TYR	SER	ASN	TRP	ILE	ILE	THR	ALA	ALA	TRP	TYR	ASN	VAL	TRP	TYR	
Oleanolic acid	2	TYR	SER	ASN	TRP	ILE	ILE	THR	ALA	ALA	PHE	TYR	ASN	VAL	TRP		
Mangiferin	4	TYR	SER	ASN	TRP	ILE	THR	ALA	PHE	TRP	TYR	TYR					
Quercetin	4	ILE	TYR	SER	ILE	THR	THR	TRP	TYR	ASN	TYR	CYS	TYR				
Caryophyllene	4	ILE	ASP	TYR	SER	TRP	TYR	TYR	CYS	TYR							
Luteolin	3	ILE	ASP	TYR	ILE	THR	THR	TRP	TYR	TYR	CYS	TYR					
Loperamide	4	TYR	SER	ASN	VAL	TRP	LEU	THR	THR	ALA	PHE	TRP	TYR	ASN	VAL	TYR	


**Docking Pose**

**Figure 3.1: Limonene with M3 muscarinic acetylcholine receptor -PDB- 4U14**







**Figure 3.5: Beta Amyrin with M3 muscarinic acetylcholine receptor -PDB- 4U14**




**Figure 3.6: Betulinic acid with M3 muscarinic acetylcholine receptor -PDB- 4U14**




**Figure 3.7: Oleanolic acid with M3 muscarinic acetylcholine receptor -PDB- 4U14**




**Figure 3.8: Mangiferin with M3 muscarinic acetylcholine receptor -PDB- 4U14**



**Figure 3.9: Quercetin with M3 muscarinic acetylcholine receptor -PDB- 4U14**




**Figure 3.10: Caryophyllene with M3 muscarinic acetylcholine receptor -PDB- 4U14**






**Figure 3.11: Luteolin with M3 muscarinic acetylcholine receptor -PDB- 4U14**



**Figure 3.12: Loperamide with M3 muscarinic acetylcholine receptor -PDB- 4U14**



### Conclusion

The computational analysis states that the herbal preparation with bio-active compounds like Limonene,  $\alpha$ -Humulene, Cyperolone, Lupeol, Beta Amyrin, Betulinic acid, Mangiferin, Quercetin, Caryophyllene and Luteolin exhibit effective binding capacity against the target protein. Hence, it was concluded that the phytochemicals have promising anti-diarrheal activity by hindering the activity of M3 muscarinic acetylcholine receptor present in the intestinal region that mediates the diarrhoea.

**Conflict of Interest:** Nil

### References

1. Das K. Textbook of medicine.6 ed. New Delhi ; Panama: Jaypee, The Health Sciences Publisher; 2017. 499-51s0p.

2. Chen J, Wan C-M, Gong S-T, Fang F, Sun M, Qian Y, et al. Chinese clinical practice guidelines for acute infectious diarrhea in children. *World Journal of Pediatrics*. 2018;14[5]:429–36.

3. Wenzl HH. Diarrhea in chronic inflammatory bowel diseases. *Gastroenterology Clinics of North America*. 2012;41[3];651–75.

4. Lopman BA, Steele D, Kirkwood CD, Parashar UD. The vast and varied global burden of norovirus: Prospects for prevention and control. *PLOS Medicine*. 2016;13[4].

5. International Institute for Population Sciences [IIPS], 2010. District Level Household and Facility Survey [DLHS-3], 2007-08: India. Mumbai: IIPS.

6. National Family Health Survey [NFHS-4] 2015-16: India [Internet]. [cited 2023 Dec 2]. Available from: <https://ruralindiaonline.org/en/library/resource/national-family-health-survey-nfhs-4-2015-16-india/>

7. WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants and children [Internet]. World Health Organization; [cited 2023 Dec 2]. Available from: <https://www.who.int/publications-detail-redirect/9789241548083>
8. Awe EO, Kolawole SO, Wakeel KO, Abiodun OO. Antidiarrheal activity of *Pyrenacantha staudtii* engl. [Iccacinaceae] aqueous leaf extract in rodents. *Journal of Ethnopharmacology*. 2011;137[1];148–53.
9. Center for Drug Evaluation and Research. FDA warns about serious heart problems [Internet]. FDA; [cited 2023 Dec 2]. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-heart-problems-high-doses-antidiarrheal>
10. Alam S, Bhatnagar S. Current status of anti-diarrheal and anti-secretory drugs in the management of acute childhood diarrhea. *The Indian Journal of Pediatrics*. 2006;73[8];693–6.
11. Kannusamy pillai C. *Sigitcha Rathina Deepam* part 1. 1<sup>st</sup> edition. Chennai; Rathina nayagar and sons publications; 1951; 28-124.
12. Wess J. Molecular biology of muscarinic acetylcholine receptors. *Critical ReviewsTM in Neurobiology*. 1996;10[1];69–99.
13. Caulfield MP, Birdsall NJM. International union of pharmacology. XVII Classification of muscarinic acetylcholine receptors. *Pharmacol Rev*. 1998;50;279–290.
14. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. *Nat Rev Drug Discov*. 2007;6;721–733
15. Yamada M, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. *Nature*. 2001;410;207–212.
16. Poulin B, et al. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. *Proc Natl Acad Sci USA*. 2010;107;9440–9445.
17. Gautam D, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. *Proc Natl Acad Sci USA*. 2009;106;6398–6403.
18. Shahedur Rahman and Rashida Parvin. Therapeutic potential of *Aegle marmelos* [L.]-An overview. *Asian Pac J Trop Dis*. 2014 Feb; 4[1]; 71–77.
19. Arunagiri Kamala, Sushil Kumar Middha. Plants in traditional medicine with special reference to *Cyperus rotundus* L.: a review. *3 Biotech*. 2018; 8[7]; 309.
20. Nagalakshmi. Phytochemical Profile of Crude Seed Oil of *Wrightia tinctoria* R.BR. and *Wrightia arborea* [DENNST.] MABB. by GC-MS. *Int. J. Pharm. Sci. Rev. Res.*, 31[2], 2015; 46-51.
21. Acharya N, Acharya S, Shah U, Shah R, Hingorani L. A comprehensive analysis on *Symplocos racemosa* Roxb.: Traditional uses, botany, phytochemistry and pharmacological activities. *J Ethnopharmacol*. 2016; 181;236-51.
22. Santosh Kumar Maurya. *Bombax ceiba* Linn. A review of its phytochemistry and pharmacology. *Current Research Journal of Pharmaceutical and Allied Sciences*. 2018;2[3];14-23.
23. Neha Grover. Phytochemical characterization using various solvent extracts and GC-MS Analysis of methanolic extract of *woodfordia fruticosa* [L.] Kurz. *Leaves*. *Int J Pharm Pharm Sci*. 2013; 5[4]; 291-295.
24. Singh A, Lal UR, Mukhtar HM, Singh PS, Shah G, Dhawan RK. Phytochemical profile of sugarcane and its potential health aspects. *Pharmacogn Rev*. 2015 Jan-Jun;9[17];45-54.
25. Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. *J Cheminform*. 2009[9];1;15.
26. Halgren TA. Merck Molecular Force Field. I. Basis, form, scope, parameterization, and performance of MMFF94. *Journal of Computational Chemistry*. 1996;17[5–6];490–519.
27. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *Journal of Computational Chemistry*. 1998;19[14];1639–62.
28. Solis FJ, Wets RJ-B. Minimization by random search techniques. *Mathematics of Operations Research*. 1981;6[1];19–30.
29. Shoeb A., Randhir S., Popli S.P. Coumarins and alkaloids of *Aegle marmelos*. *Phytochemistry*. 1973;12:2071–2072.
30. Hu QP, Cao XM, Hao DL, Zhang LL. Chemical Composition, Antioxidant, DNA Damage Protective, Cytotoxic and Antibacterial Activities of *Cyperus rotundus* Rhizomes Essential Oil against Foodborne Pathogens. *Sci Rep*. 2017 Mar 24;7:45231
31. Acharya N, Acharya S, Shah U, Shah R, Hingorani L. A comprehensive analysis on *Symplocos racemosa* Roxb.: Traditional uses, botany, phytochemistry and pharmacological activities. *Journal of Ethnopharmacology*. 2016;181:236-251.
32. Ahmad M, Jahan N, Rehman AB, Muhammad S. Antidiarrhoeal, Anti-inflammatory and analgesic activities of *Symplocos racemosa roxb*. *Bark. Pak J Pharm Sci*. 2014; Conference Issue, Vol.27[6];2221-2226.
33. Rao B, Rajeswari D, Devarakonda R, Battu H. Phytochemical and pharmacological studies on *Wrightia tinctoria*. *World J. Pharm. Pharm. Sci*. 2019.
34. Uday M, Kishor D, Ajay RA. Pharmacognostic and pharmacological overview on *Woodfordia fruticosa* Kurz. *Scholars Academic Journal of Pharmacy*. 2014;3[5]:418-22.
35. Rani S, Rahman K, Sultana A. Ethnomedicinal and pharmacological activities of *Mochrus* [*Bombax ceiba* Linn.]: An overview. *CELLMED*. 2016;6[1]:2-1.
36. Di Bosco AM, Grieco P, Diurno MV, Campiglia P, Novellino E, Mazzoni O. Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors. *Chem Biol Drug Des*. 2008 Apr;71(4):328-35.s
37. Castangia I, Nacher A, Caddeo C, Merino V, Díez-Sales O, Catalán-Latorre A, et al. Therapeutic

- efficacy of quercetin enzyme-responsive nanovesicles for the treatment of experimental colitis in rats. *Acta Biomaterialia*. 2015;13;216–27.
38. Guazelli CF, Fattori V, Colombo BB, Georgetti SR, Vicentini FT, Casagrande R, et al. Quercetin-loaded microcapsules ameliorate experimental colitis in mice by anti-inflammatory and antioxidant mechanisms. *Journal of Natural Products*. 2013;76[2];200–8.
39. Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. *Journal of ethnopharmacology*. 2018;225;342-58.
40. Wang S, Cao M, Xu S, Shi J, Mao X, Yao X, et al. Luteolin alters macrophage polarization to inhibit inflammation. *Inflammation*. 2019;43[1];95–108.
41. Nunes C, Almeida L, Barbosa RM, Laranjinha J. Luteolin suppresses the JAK/STAT pathway in a cellular model of intestinal inflammation. *Food & Function*. 2017;8[1];387-96.
42. Ovesna Z, Vachalkova A, Horvathova K, Tothova D. Pentacyclic triterpenic acids: new chemoprotective compounds Minireview. *Neoplasma*. 2004;51[5];327-33.
43. Singh GB, Singh S, Bani S, Gupta BD, Banerjee SK. Anti-inflammatory activity of oleanolic acid in rats and mice. *Journal of Pharmacy and Pharmacology*. 1992;44[5];456-8.
44. Chen JC, Chang YS, Wu SL, Chao DC, Chang CS, Li CC, Ho TY, Hsiang CY. Inhibition of Escherichia coli heat-labile enterotoxin-induced diarrhea by *Chaenomeles speciosa*. *J Ethnopharmacol*. September,2007;113[2];233-9.
45. Emilio-Silva MT, dos Santos RD, Rodrigues V, Périco LL, da Rocha LR, Hiruma-Lima CA. Antidiarrheal activity of Limonene and Citrus aurantium L. on an experimental model of castor oil-induced diarrhea in mice.2019.
46. Dong CL, Qin Y, Ma JX, Cui WQ, Chen XR, Hou LY, Chen XY, God'spower BO, Eliphaz N, Qin JJ, Guo WX, Ding WY, Li YH. The Active Ingredients Identification and Antidiarrheal Mechanism Analysis of *Plantago asiatica* L. Superfine Powder. *Front Pharmacol*.January, 2021;11;612478.
47. Alam S, Rashid MA, Sarker MMR, Emon NU, Arman M, Mohamed IN, Haque MR. Antidiarrheal, antimicrobial and antioxidant potentials of methanol extract of *Colocasia gigantea* Hook. f. leaves: evidenced from in vivo and in vitro studies along with computer-aided approaches. *BMC Complement Med Ther*.December, 2021;21[1];119.

\*\*\*\*\*